Pneumocystis Pneumonia

Patients with systemic lupus erythematosus, especially those who are positive for anti-Sm antibodies, are at greater risk for adverse events associated with trimethoprim-sulfamethoxazole, according to data presented at the ACR Convergence 2020 virtual meeting.

Concomitant steroid-pulse treatment and baseline lymphopenia were among risk factors for pneumocystis pneumonia among a cohort of patients with rheumatic diseases receiving steroid treatment, according to findings published in Arthritis Research & Therapy.